Daming Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5835879/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 2021, 184, 2348-2361.e6.	28.9	936
2	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 2022, 185, 467-484.e15.	28.9	788
3	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, 2021, 184, 4220-4236.e13.	28.9	630
4	Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 2021, 184, 2939-2954.e9.	28.9	519
5	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell, 2021, 184, 2201-2211.e7.	28.9	442
6	Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nature Structural and Molecular Biology, 2020, 27, 846-854.	8.2	434
7	The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell, 2021, 184, 2183-2200.e22.	28.9	331
8	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host and Microbe, 2020, 28, 445-454.e6.	11.0	298
9	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nature Structural and Molecular Biology, 2020, 27, 950-958.	8.2	268
10	Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2. Nature Microbiology, 2019, 4, 414-419.	13.3	73
11	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. Cell Host and Microbe, 2022, 30, 53-68.e12.	11.0	52
12	Atomic structure of the Epstein-Barr virus portal. Nature Communications, 2019, 10, 3891.	12.8	28
13	Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10. Nature Communications, 2020, 11, 38.	12.8	28
14	Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71. Nature Communications, 2020, 11, 5253.	12.8	11
15	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. Theranostics, 2022, 12, 1-17.	10.0	6